Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(A 443654; A443654)
A-443654 Chemical Structure
|Product name: A-443654|
|Cat. No.: HY-10425|
A-443654 is a potent small-molecule inhibitor of all three Akt serine/threonine kinases, induces Akt Ser-473 phosphorylation in all human cancer cell lines tested, including PTEN- and TSC2-deficient lines.
IC50 value: 0.16 nM(Ki, Akt1) 
A-443654 (Ki = 160 pmol/L versus Akt1) inhibits Akt-dependent signal transduction in cells and in vivo in a dose-responsive manner . Rapamycin and A-443654 in combination produced the greatest morphological changes and inhibited cell proliferation by G2/M arrest. Rapamycin and A-443654 in combination induced apoptosis at earlier times and at lower A-443654 concentrations in MCF10CA1a tumor cells than in the benign MCF10A cells . One small molecule, A-443654, showed the greatest selective inhibition of cells with the mutant phenotype. Based on these findings, this inhibitor was screened in vitro against a panel of glioblastoma multiforme cell lines. All cell lines tested were sensitive to A-443654 with a mean IC(50) of approximately 150 nmol/L .
|M.Wt||397.47||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||2.5159 mL||12.5796 mL||25.1591 mL|
|5 mM||0.5032 mL||2.5159 mL||5.0318 mL|
|10 mM||0.2516 mL||1.2580 mL||2.5159 mL|
3CAI is a potent allosteric and specific AKT inhibitor, which exerts efficacy in vitro and in vivo.
Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity.
ARQ-092 is an Akt inhibitor extracted from patent US/20150299195A1, compound A.
Astragalus polysaccharide, as one kind of biological macromolecule extracted from Astragalus, has antiviral activities.
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity; AKT, p70S6K, PKA, ROCK, and SGK inhibitor.
AZD5363, a novel pyrrolopyrimidine-derived compound, inhibits all AKT isoforms (IC50 <10 nM).
BAY1125976 is a selective allosteric AKT1/2 inhibitor; inhibits AKT1 and AKT 2 activity with IC50 values of 5.2 nM and 18 nM at 10 (mu)M ATP, respectively.
CCT128930 is a novel potent ATP-competitive, selective Akt2 inhibitor with an IC50 of 6 nM; >28-fold selectivity for Akt2 than the closely related PKA kinase.
Deguelin, a naturally occurring rotenoid, is known to be an Akt inhibitor and to have an anti-tumor effect on several cancers; decrease levels of phosphorylated Akt.
LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK, extracted from patent WO/2012097039A1, compound example 1, has an IC50 of 64.9 nM, 42.1 nM, 10.6 nM, 19.1 nM for Akt1(pT308), Akt1 (pS473), P70S6(pT389), S6RP(pS240/242).